Accelerated Pharma

From Verify.Wiki
Jump to: navigation, search
Accelerated Pharma
Type Public
Industry Pharmaceutical
Founded 2014
Headquarters Burr Ridge, Illinois, United States
Key people Michael Fonstein (CEO), Randy S. Saluck J.D (CFO), Ekaterina Nikolaevskaya (COO), Dmitry Prudnikov (Chief Medical Officer) [1]
Number of employees 7 [2]

Accelerated Pharma, Inc., a clinical stage pharmaceutical company, focuses on the development of pharmaceutical products for the treatment of various cancer indications. [3] It has a potential blockbuster cancer drug, Picoplatin, which is progressing towards Phase II trials. Picoplatin is a next generation platinum-based chemotherapy that may offer significant improvement over current standards of care.
It has received around $250k Debt Financing on May 4, 2016 and filed an IPO with plans to raise $17 million by offering 1.9 million shares at a price range of $8 to $10 [4]


Picoplatin is their lead product. Its exclusive features are:

  • The company’s first acquisition is Picoplatin
  • Picoplatin has the potential for use in different formulations
  • It can work as a single agent or in combination with other anti-cancer agents
  • It works to treat multiple cancer indications.
  • More then 20 clinical trials with Picoplatin in approximately a thousand cancer patients have been performed up to date.
  • The company holds an exclusive, worldwide licensee of patented and proprietary technology related to Picoplatin.
  • The company intends to further develop these drugs through multi-national trials under the guidance of both the FDA and foreign regulatory agencies



None Reported

Top 5 Recent Tweets

November 13, 2015DiseasePrimersSoluble urokinase receptor is associated with incident #CKD and an accelerated decline in kidney function. @nejm
March 22, 2019SuccessfulPRA good piece from the Outsourcing-Pharma editorial team, 'Trial recruitment platform tapped by health care network'…
March 18, 2019NeverGiveUp686By millions who have literature of love and acceptance, yet you look all around you and we teach and thrive off hat…
March 18, 2019BioPharmaReport.@NorthwellHealth taps @Clinithink's CLiX for accelerated patient identification in #clinicaltrials and research.

Top 5 Recent News Headlines

  • Cancer therapies accelerate: Accelerated Pharma files and sets terms for $17 million IPO - The Westport, CT-based company plans to raise $17 million by offering 1.9 million shares at a price range of $8 to $10. [6]
  • AzurRX discounts $5M IPO as Accelerated Pharma files for $17M offering -AzurRX gets off its IPO, but at a downsized offering, while Accelerated Pharma hopes to get off its proposed $17 million offering. [7]
  • BRIEF-Accelerated Pharma files for IPO of up to $36.7 mln - Accelerated Pharma - Applied To Have Common Stock Listed On The Nasdaq Capital Market Under The Symbol "ACCP". [8]
  • Accelerated Pharma Announces Expected Price Range for IPO - At the maximum price, the entire offering is valued up to $21.72 million. The company intends to list its shares on the Nasdaq under the symbol ACCP. [9]
  • Accelerated pharma services approach in Russia - The pharma industry in Russia is one of the most rapidly developing markets, and in the last two decades, many companies built new facilities and reconstructed existing plants.[10]



Verification history